Life sciences business set to float on AIM
Life sciences business OptiBiotix has announced that its majority-owned subsidiary SkinBioTherapeutics is set to undertake an IPO.
SkinBio is looking to be admitted to the AIM section of the London Stock Exchange.
It is part of plans announced in July 2016 by OptiBiotix to form separate divisions.
The plan was to give each its own technology platforms, IP portfolio and specialised teams - all autonomous with the potential for separate public listings.
A separate vehicle was incorporated in 2015, formerly called SkinBiotix,... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
